Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.

Investment firms in Boston and New York could see the biggest gains from the sale of a Raleigh drugmaker. Raleigh pharma ...

Happy Friday. Today, we talk about the stem cell fire sale at CIRM, and about the FDA’s move to release a limited batch of ...

Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...

Amarna Therapeutics and NorthX Biologics finalized an agreement to advance Nimvec AM510 gene therapy toward clinical trials for Type 1 Diabetes. Now in its fourth year, the MM+M Media Summit brings ...

U.S. appetite for U.K. companies is only intestifying in 2025; here, Law.com charts some of the highest profile deals in H1, ...

For the third time in four years, CNBC has ranked North Carolina as “America’s Top State for Business” in 2025.

Barely a day passes without intellectual property nurtured and supported in Britain passing into overseas hands.

US Foods Holding stock hit an all-time high Friday on a report that the firm was mulling an acquisition of Performance Food ...

FDA Commissioner Marty Makary suggests his agency may expedite drug reviews for manufacturers reducing U.S. prices to global ...